Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 866725 | ISIN: US6556631025 | Ticker-Symbol: ND1
Tradegate
25.06.25 | 12:06
185,20 Euro
+1,42 % +2,60
Branche
Maschinenbau
Aktienmarkt
S&P 500
1-Jahres-Chart
NORDSON CORPORATION Chart 1 Jahr
5-Tage-Chart
NORDSON CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
181,20183,7525.06.
181,20183,9025.06.
ACCESS Newswire
331 Leser
Artikel bewerten:
(2)

Quasar Medical to Acquire Nordson MEDICAL Design and Development Business in Galway, Ireland, and Tecate, Mexico

Quasar Grows Global Full-Lifecycle CDMO Platform; Nordson MEDICAL Sharpens Focus on Core Components Business

SAINT PAUL, MINNESOTA / ACCESS Newswire / May 29, 2025 / Quasar Medical, a global leader in the manufacturing of interventional and complex minimally invasive devices, announced it has signed a definitive agreement with Nordson Corporation (NASDAQ:NDSN) to acquire its design and development contract manufacturing businesses in Galway, Ireland, and Tecate, Mexico. This will strengthen Quasar's global position as a full-service Contract Development and Manufacturing Organization (CDMO), offering end-to-end solutions from initial design to large-scale production. The deal is expected to close in the third quarter of calendar 2025.

The Galway and Tecate facilities will be integrated into Quasar's expanding global platform, adding specialized expertise in complex balloon and catheter design, rapid prototyping, and cost-efficient device near-shore assembly. Both sites provide Quasar with not only advanced know-how and IP-generating capabilities but will also add FDA-registered and ISO-certified facilities and a highly skilled workforce located in two strategic MedTech hubs.

"This is more than a bolt-on acquisition - it marks the next chapter for Quasar," said Alex Wallstein, CEO of Quasar Medical. "We are now positioned to deliver fully integrated interventional solutions from concept to scale-up finished device, adding significant capacity in Ireland and Mexico to our well-established Asian footprint - diversifying Quasar into a global CDMO partner."

Dave Zgonc, Vice President of Nordson MEDICAL Interventional Solutions, said, "We're extremely proud of the highly skilled teams in Galway and Tecate, their expertise, and the customer partnerships they've built over the years in our finished device contract manufacturing business. We are thankful for their commitment and dedication to this business."

EXPANDED CAPABILITIES, GLOBAL REACH

With this acquisition, Quasar Medical now operates 10 facilities across North America, Europe, Israel, and Asia, providing added expertise in design, development, balloon catheter systems, micro-EM sensors, and rapid scale-up of low-cost assembly and manufacturing.

  • 800,000 square feet of manufacturing space

  • Over 4,200 employees, including over 50 NPD Engineers

  • FDA-registered and ISO 13485 certified

  • Galway: design, prototyping, and product development, as well as manufacturing

  • Tecate: cost-effective, scalable device manufacturing and assembly

CUSTOMER BENEFITS & STRATEGIC IMPACT

Quasar Medical's customers will benefit from:

  • Integrated design-for-manufacturing and scalable production

  • Seamless program transfers and faster market readiness

  • Near-shore operations for U.S. customers

  • Regionally optimized manufacturing strategies balancing speed, quality, and cost

  • Robust quality infrastructure with FDA and ISO 13485 compliance across all facilities

This strategic step expands Quasar's ability to support global OEMs and innovators with speed, flexibility, innovation, and precision - from concept to prototype to finished device delivery.

Quasar will work closely with Nordson to ensure a smooth transition for all customers and suppliers. Upon closing, the Galway and Tecate sites will be fully integrated into the Quasar platform.

Quasar Medical is a global Contract Development and Manufacturing Organization (CDMO) delivering end-to-end solutions for interventional and minimally invasive medical devices. With 10 global facilities and 4,200 employees across Asia, North America, and Europe, Quasar specializes in catheter systems, balloon technologies, micro-EM sensors, and complex assemblies. Headquartered in Singapore, the company offers fully integrated device solutions spanning design, prototyping, and scalable manufacturing. Quasar operates under ISO 13485:2016 and cGMP standards, serving leading medical device OEMs and innovators worldwide. For more information, visit?www.quasarmedical.com.

Nordson MEDICAL?is a global expert in the design, development and manufacturing of medical component technologies and proprietary technologies and devices. Our extensive breadth of solutions serves interventional, surgical and specialized markets with technologies that save or enhance lives. As an integrated partner, Nordson MEDICAL enables customers to save costs and speed time to market. For more information, visit www.nordsonmedical.com.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top-tier growth with leading margins and returns. The Company's direct sales model and applications expertise serve global customers through a wide variety of critical applications. Its diverse end-market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.

Contact Information

Jackie Rauchberger
Senior Director Global Marketing, Quasar Medical
marketingpr@quasar-med.com
(651) 641-4034

Lara Mahoney
Vice President, Corporate Communications and Investor Relations, Nordson Corporation
440-204-9985

.

SOURCE: Quasar Medical

Related Images



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/quasar-medical-to-acquire-nordson-medical-design-and-development-busi-1033146

© 2025 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.